![]() Financial Daily from THE HINDU group of publications Sunday, February 16, 2003 |
|
|
|
|
|
MARKETS MUTUAL FUNDS Zurich India Top 200 Fund: Invest IN TERMS of its portfolio strategy, the Zurich India Top 200 Fund lies midway between aggressive equity funds, which rely wholly on the stock selection skills of their fund manager, and passive index funds, which merely mimic the returns on stock ... More
Tata MF's Ind Tax Shield: Positioned differently now
US-64 trades: Senseless or sinister?
Prudential ICICI Power: Hold
Zurich India Capital Builder: Sell
Franklin Prima: Invest STOCK MARKETS World Cup snips bourses' turnover IF capturing eyeballs is what broadcasters want, then stock market functionaries did not disappoint them last week. With turnover and volumes down by 20 per cent on both the BSE and NSE, ever since the World Cup began, the Indian stock ... More DERIVATIVES MARKETS Basics of Nifty futures A FUTURES contract is a forward contract, which is traded on an Exchange. NSE commenced trading in index futures on June 12, 2000. The index futures contracts are based on the popular market benchmark S&P CNX Nifty index.NSE defines the ... More
HPCL calls remain firm REGULATORY BODIES & RULINGS `Portfolio managers can deal in derivatives thru stock exchanges' PROVIDING clarity to the recent amendments to the regulations on portfolio managers, the Securities and Exchange Board of India (SEBI) said that the portfolio managers were permitted to invest in derivatives, including transactions for the ... More COMMENTARY HLL: On the verge of an uptrend NIFTY (1036): The growing threat of a US-led attack on Iraq continued to dominate proceedings during the week gone by. As mentioned last week, the drop below 1045 imparted bearish trend, pushing the Nifty to a low of 1034.1 on ... More
Reduce exposure in United Phosphorous
Nasdaq: Short-term recovery
Market rumours on ADR issue pull Infosys down RECOMMENDATION Dabur India: Buy FOR a company which combines a formidable array of FMCG and ayurvedic healthcare brands in its portfolio and also manages a thriving pharmaceutical business, Dabur India has not enjoyed a very high stock valuation on the bourses. It trades at a ... More
Grasim: Hold
Henkel SPIC: Pare exposures
A complex game waiting to be played out
Aventis Pharma: Hold
TVS Srichakra: Book profits
ABB India: Good medium term bet PUBLIC OFFERS Divi's Labs: Reactive INVESTORS can consider subscribing to the public offer of the Hyderabad-based Divi's Laboratories at the floor price of Rs 130. The company derives a substantial portion of its revenues by supplying active pharmaceutical ingredients (API) to drug ... More Stock Quotes SE Diary Comments & Letters to the Editor to: bleditor@thehindu.co.in Subscribe to: Business Line |
![]() ![]() Pick a Winner Stock Market Contest
Top Stories In Focus Kelkar Report Telecom Competition Oil PSUs: Disinvestment dilemma Housing Fin. rate war: Bonanza for consumers! NPAs in Banking In Depth Simple Economics Consumer Notes Tax Talk The Brahmananda collections 2002: A drought year Gold: Still the winner? Cars: Always a beauty Books and Reviews Looking back Feb. 9-Feb. 15 `Market rewards performing cos' Mr Raamdeo Agrawal, Joint MD, Motilal Oswal Securities E-balance sheets on cards? |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home | Copyright © 2003, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line |